Topics
Glioblastoma | Treatment | Clinical trials | Nivolumab (Anti-programmed cell death protein 1)
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Nivolumab
2024
Sloan
AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N,
Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M,
Mehta MP.
NRG-BN002:
Phase I Study of Ipilimumab, Nivolumab, and the Combination in
Patients with Newly Diagnosed GBM.
Neuro
Oncol.
2024 Jun 14:noae058. doi:
10.1093/neuonc/noae058. PMID:
38874333. Interventional study˰ ˍ
2025
Wen PY, Manzanera A, Duault C, Gonzalez-Kozlova E, Lopez L,
Grossman SA, Ye X, Fisher J, Lee I, Walbert T, Snyder J, Brem S,
Desai A, Bagley SJ, Kakani C, Strowd R, Tatter S, Laxton A, Lesser
G, Amankulor N, Lieberman F, Drappatz J, Mantica M, Triggs D,
Haymaker C, Wistuba II, Al-Atrash G, Mendoza Perez J, Futreal A,
Little LD, Islam MDH, Duose D, Jiang P, Reuben A, Lawler SE,
Pichavant M, Gentles A, Bendall S, Kong A, Camacho C, Del Valle D,
Kim-Schulze S, Gnjatic S, Sharon E, Nowicki MO, Peruzzi P, Lane D,
Aguilar-Cordova E, Aguilar LK, Nichols G, Dwyer J, Tak PP, Maecker
H, Barone F, Chiocca EA.
A
multi-institutional phase 1 clinical trial exploring upfront
multimodal standard of care and combined immunotherapies for newly
diagnosed glioblastoma.
Neuro
Oncol. 2025 Mar 22:noaf079. doi:
10.1093/neuonc/noaf079. PMID:
40120123. Interventional study˰
ˍ
Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD,
Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman
EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl
M, Galbraith K, Dignam JJ, Won M, Mehta MP.
Dual
Immune Check Point Blockade in MGMT-Unmethylated
Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized
Phase II/III Clinical Trial.
J
Clin Oncol. 2025 Aug 8:JCO2500618. doi:
10.1200/JCO-25-00618. PMID:
40779733. Interventional study. ˍ
NRGoncology.org
ID: NRG-BN007.
Neuro-Oncology Clinical Research Program; Camphausen K.
Phase
II Trial Evaluating the Association of Peripheral Blood
Immunologic Response to Therapeutic Response After Adjuvant
Treatment with Immune Checkpoint Inhibition (ICI) in Patients with
Newly Diagnosed Glioblastoma or Gliosarcoma.
medRxiv
[Preprint]. 2025 Dec 30:2025.12.23.25342908. doi:
10.64898/2025.12.23.25342908. PMID:
41607658. Trial
registration ID: NCT04817254. ˍ
2026
Lukas RV, Zhai L, Lauing KL, Kim M, Koch T, Penco-Campillo M,
Bommi P, Dixit K, Kumthekar P, Sharp L, Lezon R, Garcia D,
Sonabend AM, McCortney K, Castro BA, Chandler JP, Gondi V, Grimm
SA, Miska JM, Heimberger AB, Dobinda K, Zhang H, Sachdev S, Juhasz
C, James CD, Allen JM, Horbinski C, Lesniak MS, Stupp R,
Wainwright DA.
Phase 1 evaluation of
patients with newly diagnosed glioblastoma treated with radiation,
nivolumab, and IDO1 enzyme inhibitor BMS-986205.
Clin
Cancer Res. 2026 May 26. doi:
10.1158/1078-0432.CCR-26-1124. PMID:
42189896. Trial
registration ID: NCT04047706.
ˍ
Lim M, Ye X, Piotrowski AF, Desai A, Ahluwalia MS, Walbert T,
Lesser G, Ellingson BM, Peereboom DM, Fisher JD, Desideri S,
Jackson C, Pant A, Jain A, Verma R, Oberlton B, Piyadasa H,
Bettegowda C, Engle L, Taube J, Bendall SC, Choi J, Drappatz J,
Lieberman FS, Kleinberg LR, Pardoll DM, Nabors LB, Wen PY,
Grossman SA.
Anti-LAG-3 with or
without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.
Nat
Med. 2026 Jul 10;32(7):2449-2460. doi:
10.1038/s41591-026-04475-7. PMID:
42432293. Trial
registration ID: NCT02658981. ˍ
Sun L, Markus LF, Sanchez JC, Lai TJ, Lee EQ, Li G, Kim J, Zhuang
Z, Acevedo B, Everson RG, Mellinghoff IK, Aquilanti E, Nicolas
Gonzalez Castro L, Ricardo McFaline-Figueroa J, Nayak L, Beroukhim
R, Chong RA, Stone J, Kaley T, Schaff L, Wilcox J, Westergaard C,
Russ A, Lavallee M, Chukwueke U, Van den Abbeele AD, Lim M,
Ellingson BM, Reardon DA, Cloughesy TF, Prins RM, Wen PY.
Neoadjuvant PD1 plus CTLA-4 immune
checkpoint blockade in surgically resectable recurrent
glioblastoma: a randomized surgical window-of-opportunity trial.
Nat
Commun. 2026 Sep 5;17(1):10560. doi:
10.1038/s41467-026-77433-z. PMID:
42838943. Trial
registration ID: NCT04606316. ˍ